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Abstract. CXC ligand (L)12 is a chemokine implicated in the 
migration, invasion and metastasis of cancer cells via interac‑
tion with its receptors CXC chemokine receptor (CXCR)4 and 
CXCR7. In the present study, CXCL12‑mediated Ca2+ signal‑
ling was compared with two basal‑like breast cancer cell lines, 
MDA‑MB‑231 and MDA‑MB‑468, which demonstrate distinct 
metastatic potential. CXCL12 treatment induced Ca2+ responses 
in the more metastatic MDA‑MB‑231 cells but not in the less 
metastatic MDA‑MB‑468 cells. Assessment of mRNA levels of 
CXCL12 receptors and their potential modulators in both cell 
lines revealed that CXCR4 and CXCR7 levels were increased 
in MDA‑MB‑231 cells compared with MDA‑MB‑468 cells. 
Cluster of differentiation (CD)24, the negative regulator of 
CXCL12 responses, demonstrated increased expression in 
MDA‑MB‑468 cells compared with MDA‑MB‑231 cells, and the 
two cell lines expressed comparable levels of hypoxia‑inducible 
factor (HIF)2α, a CXCR4 regulator. Induction of epithelial‑
mesenchymal transition (EMT) by epidermal growth factor 
exhibited opposite effects on CXCR4 mRNA levels compared 
with hypoxia‑induced EMT. Neither EMT inducer exhibited 
an effect on CXCR7 expression, however hypoxia increased 
HIF2α expression levels in MDA‑MB‑468 cells. Analysis of 
the gene expression profiles of breast tumours revealed that the 
highest expression levels of CXCR4 and CXCR7 were in the 
Claudin‑Low molecular subtype, which is markedly associated 
with EMT features.
Introduction
Chemokines are a superfamily of small (~8‑14 kDa) molecules 
that mediate numerous cellular functions by activating G 
protein‑coupled receptors (1). Chemokines and their respective 
receptors are also associated with metastasis in different types 
of cancer, including osteosarcoma (2) and neuroblastoma (3), 
as well as prostate (4) and breast (5) cancer. The chemokine 
CXC ligand 12 (CXCL12; also known as stromal cell‑derived 
factor‑1) is implicated in numerous cellular processes that 
are important in aspects of tumour progression. It interacts 
with its cognate receptors CXC chemokine receptor (R) type 
4 (1) and CXCR7 (6) to regulate cell trafficking and adhesion, 
tumour vascularisation, cell proliferation and survival (7,8). 
CXCL12 enhances the invasiveness and migratory proper‑
ties of breast cancer cells, particularly when these cells also 
express CXCR4 (9). Indeed, CXCR4 expression is upregulated 
in primary breast tumours compared with normal mammary 
epithelial cells (5) indicating that it serves an important func‑
tion in the progression and metastasis of breast cancer (10,11).
CXCL12 responses are regulated by other factors beyond 
its receptors CXCR4 and CXCR7. Among these factors is 
cluster of differentiation (CD)24, a glycosylated cell surface 
protein that acts as a signal transducer in modulating responses 
to B cell activation (12). Schabath et al (13) demonstrated that 
MDA‑MB‑231 breast cancer cells with low CD24 expression 
exhibit augmented CXCL12/CXCR4‑mediated cell migration 
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and enhanced tumour growth compared with MDA‑MB‑231 
cells that express high exogenous levels of CD24, suggesting 
that higher CD24 expression decreases CXCL12 responses in 
breast cancer cells. Hypoxia‑inducible factor‑2α (HIF2α) also 
regulates CXCR4 expression (14) and may therefore influence 
CXCL12 responsiveness.
Certain cells respond to CXCL12 activation by releasing 
Ca2+ from the endoplasmic reticulum internal Ca2+ store 
via G‑protein coupled receptor, triggering phospholipase C 
activation and the generation of inositol trisphosphate and 
diacylglycerol (7). Ca2+ signalling is associated with processes 
that occur during metastasis, including cell migration and 
invasion (15,16), as well as the induction of an increasingly 
invasive phenotype by stimulating the epithelial‑mesenchymal 
transition (EMT) (17). EMT is a process whereby epithelial 
cells undergo conversion to an increasingly mesenchymal 
(invasive) phenotype (18). However, the nexus between 
CXCL12, Ca2+ signalling, CXCL12 modulators and receptors 
and EMT has not yet been fully evaluated.
The nature of Ca2+ store release as a result of 
CXCL12/CXCR4 interaction may be tissue‑dependent and 
vary between cell types (7). Changes in Ca2+ signalling and/or 
the expression of specific modulators of Ca2+ signalling are a 
feature of some subtypes of breast cancer and these changes 
often differ between different breast cancer subtypes. For 
example, the ratio of the calcium release‑activated calcium 
channel protein (Orai)1 calcium influx pathway activators 
stromal interaction molecule 1/2 is higher in the basal molec‑
ular breast cancer subtype than in other subtypes (19). It has 
been demonstrated that Orai3 regulates store‑operated Ca2+ 
entry in oestrogen receptor‑positive breast cancer cell lines 
such as MCF‑7 but does not in oestrogen receptor‑negative 
breast cancer cell lines such as MDA‑MB‑231 (20). Elevated 
transient receptor potential cation channel V6 levels are 
more common in types of breast cancer that are oestrogen 
receptor‑negative (21). Oestrogen receptor‑negative breast 
cancer, particularly those of the triple‑negative subtype, 
exhibit a significant overlap with molecularly defined basal 
breast cancer (22).
Basal breast cancer cell lines possess gene signatures that 
allow them to be divided into basal A and basal B subtypes (23). 
In the present study, Ca2+ signalling induced by CXCL12 was 
compared between two triple‑negative basal breast cancer cell 
lines, MDA‑MB‑468 (basal A) and MDA‑MB‑231 (basal B). 
mRNA levels of CXCL12 receptors and their response modu‑
lators in EMT and in breast cancer cell lines of different 
molecular subtypes were also characterised. The present 
study therefore aimed to assess the potential heterogeneity of 
responses to CXCL12 in the context of induced Ca2+ increases 
in basal breast cancer.
Materials and methods
Cell culture. The human basal‑like triple‑negative breast 
cancer cell lines MDA‑MB‑231 and MDA‑MB‑468 were 
obtained from the American Type Culture Collection 
(Manassas, VA, USA) and The Brisbane Breast Bank, 
University of Queensland Centre for Clinical Research, 
(Brisbane, Australia) respectively, and maintained in 
Dulbecco's modified Eagle's medium (DMEM; D6546; 
Sigma‑Aldrich; Merck KGaA, Darmstadt, Germany) supple‑
mented with 10% foetal bovine serum (FBS; Sigma‑Aldrich; 
Merck KGaA), L‑glutamine (4 mM; Invitrogen; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA), penicillin 
100 U/ml and streptomycin 100 µg/ml (Invitrogen; Thermo 
Fisher Scientific, Inc.) in a humidified incubator at 37˚C in 
an atmosphere containing 5% CO2. Cells were routinely 
screened for mycoplasma contamination using the MycoAlert 
Mycoplasma Detection kit (LT07‑218; Lonza Group, Ltd., 
Basel, Switzerland) and validated by short tandem repeat 
profiling using the StemElite ID Profiling kit (Promega 
Corporation, Madison, WI, USA).
Intracellular Ca2+ measurement. For Ca2+ measurements, 
MDA‑MB‑231 (7.5x103 cells/well) or MDA‑MB‑468 
(1.5 x104 cells/well) cells were seeded in a 96‑well CellBIND 
plate (Corning Life Sciences, Corning, NY, USA) in antibi‑
otic‑free DMEM containing L‑glutamine (4 mM) and 10% 
FBS (MDA‑MB‑468 cells were seeded at a higher density 
due to their slower proliferation rate). At 24 h post‑plating, the 
FBS concentration was decreased to 8%. At 72 h post‑plating, 
Ca2+ assays were performed using a fluorescence imaging plate 
reader, FLIPRTETRA (Molecular Devices, LLC, Sunnyvale, CA, 
USA) and 4 µM Fluo‑4 AM dye (Molecular Probes; Thermo 
Fisher Scientific, Inc.) in physiological salt solution, as previously 
described (24). Cells were excited at 470‑495 nm and emission 
was assessed at 515‑575 nm over an 800 sec period. Relative 
cytoplasmic (CYT) [Ca2+]CYT was determined in the presence 
of 300 and 100 ng/ml recombinant human CXCL12 (R&D 
Systems, Inc., Minneapolis, MN, USA) or 100 µM adenosine 
5'‑triphosphate (ATP; Sigma‑Aldrich; Merck KGaA). Data were 
acquired using ScreenWorksTM software (v2.0.0.27, Molecular 
Devices, LLC) and are presented as the response over baseline, 
which is a measure of relative [Ca2+]CYT.
RNA isolation and reverse transcription‑quantitative 
polymerase chain reaction (RT‑qPCR). Total RNA was 
isolated using the RNeasy® Plus Mini kit (Qiagen GmbH, 
Hilden, Germany). RT reactions were performed using an 
Omniscript Reverse Transcriptase kit (Qiagen GmbH) with 
random primers and RNase inhibitor (Promega Corporation), 
according to the manufacturer's protocol. qPCR was 
conducted using Applied Biosystems TaqMan gene expres‑
sion assays and TaqMan Universal PCR Master mix (Applied 
Biosystems; Thermo Fisher Scientific, Inc.). Assays included 
CD24 (Assay ID: Hs02379687_s1), CXCR4 (Assay ID: 
Hs00237052_m1), CXCR7 (Assay ID: Hs00664172_s1), 
HIF2α (Assay ID: Hs01026149_m1) and the endogenous 
control 18S ribosomal RNA (4319413E). All amplifications 
were performed using universal cycling conditions [20 sec at 
95˚C (holding stage)], followed by 40 cycles of denaturation 
for 1 sec at 95˚C and combined annealing and extension 
steps for 20 sec at 60˚C) in a StepOnePlus™ Real‑Time 
PCR System Thermal Cycling Block (Applied Biosystems; 
Thermo Fisher Scientific, Inc.). Data were normalised to 
18S ribosomal RNA and analysed using the comparative Cq 
method as previously described (25).
Epidermal growth factor (EGF)‑induced EMT. For assess‑
ment of EGF‑induced EMT, MDA‑MB‑468 cells were plated 
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at a density of 2x104 into a 96‑well plate and serum‑starved 
(0.5% FBS) for 24 h prior to treatment with 50 ng/ml EGF 
(Sigma‑Aldrich; Merck KGaA), as previously described (26). 
Total RNA was isolated at 24 h post‑EGF treatment and 
subjected to RT‑qPCR following the aforementioned protocol 
to assess the changes in CXCR4, CXCR7, CD24 and HIF2α 
expression.
Hypoxia‑induced EMT. For hypoxia‑induced EMT, 
MDA‑MB‑468 cells were seeded at a density of 2x104 in a 
96‑well plate and serum‑deprived (0.5% FBS) for 24 h. Cells 
were then exposed to hypoxic conditions (1% O2) in a Sanyo 
MCO‑18M multi‑gas incubator (Sanyo Electric Co., Ltd., 
Tokyo, Japan). Normoxic control MDA‑MB‑468 cells were 
incubated in a humidified incubator (37˚C, 5% CO2) with 
normal atmosphere (21% O2). Total RNA was isolated at 24 h 
following normoxic or hypoxic conditions to assess changes in 
CXCR4, CXCR7, CD24 and HIF2α expression, following the 
aforementioned protocol.
Analysis of CXCR4 and CXCR7 expression in breast tumours. 
Breast tumour gene expression data were sourced from the 
METABRIC breast cancer data (www.cbioportal.org, last 
accessed April 3, 2017) (27‑29). This dataset comprises gene 
expression profiles from 1,860 tumours from six molecular 
subtypes including 198 basal‑like (Basal), 182 Claudin‑low 
(C‑low), 218 human epidermal growth factor receptor 
2‑enriched (HER2), 673 luminal A (LumA), 454 luminal B 
(LumB) and 135 normal‑like (N‑Like).
Statistical analysis. Statistical analyses were performed using 
GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, 
USA). Results are expressed as the mean ± standard devia‑
tion from the specified number of independent experiments. 
Figure 1. Effect of CXCL12 on [Ca2+]CYT in MDA‑MB‑231 and MDA‑MB‑468 breast cancer cells. (A) Representative [Ca2+]CYT transients following treatment 
with 100 and 300 ng/ml CXCL12 in MDA‑MB‑231 cells. (B) Each bar represents the response (peak relative [Ca2+]CYT) to either 100 ng/ml CXCL12 or 300 ng/ml 
CXCL12 in MDA‑MB‑231 cells (n=3; mean ± standard deviation). (C) [Ca2+]CYT levels following treatment with 100 and 300 ng/ml CXCL12 in MDA‑MB‑468 
cells. Stimulation with 100 µM ATP was used as a positive control for this assay (representative of three independent experiments). (D) Presents only the 
CXCL12 response using the same maximum Y‑axis scale that was used for MDA‑MB‑231 cells. Statistical analysis was performed using one‑way analysis of 
variance with Tukey's multiple comparison post‑hoc test. **P<0.01. CXCL, CXC ligand; CYT, cytoplasmic; [Ca2+], intracellular calcium concentration.
Figure 2. CXCR4, CXCR7, CD24 and HIF2α mRNA levels in MDA‑MB‑231 
and MDA‑MB‑468 breast cancer cells normalised to 18S ribosomal RNA 
(‑ΔCq). Results were taken from three independent experiments and the 
horizontal line represents the mean (n=3). Statistical analysis was performed 
using an unpaired t‑test. *P<0.05. NS, not significant; CXCR, CXC chemo‑
kine receptor; CD, cluster of differentiation; HIF, hypoxia‑inducible factor.
JAMALUDIN et al:  CXCL12 CA2+ SIGNALLING IN BASAL BREAST CANCER CELLS4
The statistical tests used are stated in each figure legend, and 
included one‑way analysis of variance followed by Tukey's 
multiple comparison and an unpaired t‑test, where appropriate.
Results
CXCL12‑induced intracellular free Ca2+ increases in breast 
cancer cells. The effects of CXCL12 on intracellular Ca2+ 
concentrations were assessed in two basal‑like breast cancer 
cell lines, MDA‑MB‑231 (basal B) and MDA‑MB‑468 
(basal A). A significant concentration‑dependent increase 
in [Ca2+]CYT was observed following CXCL12 treatment in 
MDA‑MB‑231 breast cancer cells (P<0.01; Fig. 1A and B) 
compared with the untreated control. However, no significant 
increase in [Ca2+]CYT was observed in MDA‑MB‑468 cells 
treated with CXCL12 compared with the untreated control, 
despite a pronounced elevation in intracellular Ca2+ levels 
observed during stimulation with the purinergic receptor acti‑
vator ATP (Fig. 1C and D).
Levels of CXCR4, CXCR7, CD24 and HIF2α mRNA in 
MDA‑MB‑231 and MDA‑MB‑468 breast cancer cells. To 
explore the potential reasons for the lack of CXCL12‑induced 
[Ca2+]CYT in MDA‑MB‑468 basal A breast cancer cells, 
compared with the significant increases observed in more 
metastatic MDA‑MB‑231 basal B breast cancer cells, mRNA 
expression of the potential regulators of CXCL12 responses 
were measured. Levels of mRNA for the CXCL12 receptor 
CXCR4 were significantly increased in MDA‑MB‑231 cells 
compared with MDA‑MB‑468 cells (P<0.05; Fig. 2). Similarly, 
levels of CXCR7, another receptor for CXCL12 (6), were 
significantly increased in MDA‑MB‑231 cells compared with 
MDA‑MB‑468 cells (P<0.05; Fig. 2). CD24 is a negative regu‑
lator of CXCL12 responses in MDA‑MB‑231 cells (13) and in 
the present study, it was revealed that there were significantly 
higher levels of CD24 mRNA in MDA‑MB‑468 cells (P<0.05; 
Fig. 2), which were not responsive to CXCL12 as assessed by 
increases in [Ca2+]CYT (Fig. 1C), compared with MDA‑MB‑231 
cells. Given that an association between HIF2α and CXCR4 
expression has been identified (14), HIF2α levels were also 
assessed in the two cell lines in the present study; however, no 
significant difference was observed (Fig. 2).
Assessment of CXCR4, CXCR7, CD24 and HIF2α during 
hypoxia‑ and EGF‑induced EMT in MDA‑MB‑468 breast 
cancer cells. MDA‑MB‑231 is a basal B cell line and exhibits 
mesenchymal features, including vimentin expression and a lack 
of E‑cadherin expression (30). Given that CXCL12‑mediated 
Figure 3. mRNA levels of CXCR4, CXCR7, CD24 and HIF2α mRNA following hypoxia‑ and EGF‑induced EMT in MDA‑MB‑468 breast cancer cells 
expressed as fold change. (A) CXCR4, (B) CXCR7, (C) CD24, and (D) HIF2α mRNA levels in MDA‑MB‑468 cells incubated under normoxic or hypoxic (24 h) 
conditions or stimulated with EGF (24 h) to induce EMT. Results are presented as the mean ± standard deviation (n=3). Statistical analysis was performed using 
an unpaired t‑test; *P<0.05, **P<0.01, ***P<0.001. NS, not significant; CXCR, CXC chemokine receptor; CD, cluster of differentiation; HIF, hypoxia‑inducible 
factor; EMT, epithelial‑mesenchymal transition; EGF, epidermal growth factor.
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calcium signalling may be influenced by CXCR4, CXCR7 and 
CD24 (7,13), and that their expression differed between the more 
epithelial MDA‑MB‑468 (basal A) and the more mesenchymal 
MDA‑MB‑231 (basal B) breast cancer cell lines, the effect of 
EMT induction on CXCR4, CXCR7, CD24 and HIF2α expres‑
sion in MDA‑MB‑468 cells was assessed. In the present study 
EMT induction with two distinct inducers was assessed to 
define the changes associated with EMT rather than the stimuli. 
Our previous studies of EMT in EGF and hypoxia models in 
this cell line produced increases in levels of the mesenchymal 
markers N‑cadherin, zinc finger protein SNAI1, zinc finger 
E‑box binding homeobox 1, CD44, twist‑related protein and 
vimentin, downregulation of the epithelial markers E‑cadherin 
and Claudin‑4, as well as CD24, and changes to a more spindle 
morphology (31‑33). In the present study, EGF and hypoxia 
produced opposing effects on CXCR4 levels and did not affect 
CXCR7 levels (Fig. 3A and B). Only the mRNA level of the 
known EMT marker CD24 was significantly decreased following 
induction of the EMT by the two inducers (P<0.01; Fig. 3C). 
HIF2α mRNA levels significantly increased following hypoxia 
(P<0.05), however they were unaffected by EGF (Fig. 3D).
CXCR4 and CXCR7 expression is enriched in breast tumours 
with mesenchymal features. Assessment of gene expression 
profiles in breast tumours classified based on the differential 
expression of 50 genes (PAM50) (29), demonstrated that CXCR4 
and CXCR7 levels were higher in the C‑Low subtype compared 
with the other subtypes (Fig. 4). The C‑Low subtype is mark‑
edly associated with the EMT and stem cell‑like features (34).
Discussion
The present study identified distinct CXCL12‑induced 
Ca2+ responses between two basal‑like breast cancer 
cell lines, MDA‑MB‑231 (basal B) and MDA‑MB‑468 
(basal A). CXCL12‑mediated Ca2+ responses were observed 
in MDA‑MB‑231 cells but not in MDA‑MB‑468 cells. It 
has been demonstrated that CXCL12/CXCR4‑mediated Ca2+ 
signalling is enhanced in invasive breast cancer cell lines, such 
as MDA‑MB‑231 and BT‑549, compared with non‑metastatic 
cell lines, due to differences at the level of G protein subunit 
coupling that may prevent the activation of CXCR4 in less 
metastatic cell lines (35). The results of the present study 
expand upon these findings, as it was demonstrated that 
CXCL12‑induced increases in [Ca2+]CYT were more pronounced 
in the more metastatic MDA‑MB‑231 cell line compared with 
less metastatic MDA‑MB‑468 cells.
The potential cause of differential CXCL12‑induced Ca2+ 
signalling between MDA‑MB‑231 and MDA‑MB‑468 cells 
was explored by assessing the expression of the CXCL12 
receptors CXCR4 and CXCR7, as well as potential regulators 
of CXCL12 responses, specifically CD24 and HIF2α (13,14). 
The results of the present study demonstrate that the expres‑
sion of CXCR4 and CXCR7 is increased in MDA‑MB‑231 
cells compared with MDA‑MB‑468 cells. The presence 
of CXCR4 and CXCR7 in the two breast cancer cell lines 
supports the results of previous studies which state that 
CXCR4 and CXCR7 are expressed in a variety of human 
malignancies, including in breast and lung cancer (36,37). The 
expression of CXCR4 and CXCR7 suggests that these recep‑
tors may contribute to the CXCL12‑induced Ca2+ responses 
in MDA‑MB‑231 cells, which were observed in the present 
study. The non‑responsiveness of MDA‑MB‑468 cells to 
CXCL12 stimulation (as measured by increases in Ca2+ levels) 
may be due in part to the decreased expression of CXCR4 and 
CXCR7 in this cell line compared with MDA‑MB‑231 cells. 
Analysis of CD24 mRNA expression indicated that CD24 was 
abundantly expressed in non‑responsive MDA‑MB‑468 cells 
Figure 4. The expression of CXCR4 and CXCR7 is enriched in the C‑Low molecular subtype of breast tumours compared with the basal molecular subtype. 
Log2 expression values of (A) CXCR4 and (B) CXCR7 in 6 subtypes of breast tumours, including Basal, C‑Low, HER2, LumA, LumB and N‑Like. Data 
were sourced from the METABRIC breast cancer data (29) and analysed using www.cbioportal.org (27,28). Statistical analysis was performed using one‑way 
analysis of variance followed by Tukey's multiple comparisons post‑hoc test. *P<0.05, ****P<0.0001. NS, not significant; Basal, Basal‑Like; C‑Low, Claudin‑Low; 
HER2, human epidermal growth factor receptor 2‑enriched; LumA, Luminal A; LumB, Luminal B; N‑Like, Normal‑like; CXCR, CXC chemokine receptor.
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compared with MDA‑MB‑231 cells, a known feature of basal 
A cell lines compared with basal B (38). The differential CD24 
expression detected in the present study is also consistent with 
the results of a previous study by Schindelmann et al (39); 
although this study did not assess MDA‑MB‑468 cells, it was 
reported that CD24 mRNA levels are generally increased in 
non‑invasive breast cancer cell lines compared with invasive 
cell lines. The significant upregulation of CD24 observed in 
MDA‑MB‑468 cells may have also contributed to the attenu‑
ation of CXCL12‑mediated Ca2+ signalling in this cell line, 
given that CD24 interferes with CXCL12/CXCR4‑mediated 
cell migration and tumour growth in pre‑B lymphocytes and 
breast cancer cells (13). By contrast, levels of HIF2α, which 
has been demonstrated to modulate CXCR4 expression (14), 
did not differ significantly between the two cell lines, there‑
fore it is unlikely to have contributed to any differences in 
CXCL12‑mediated Ca2+ signalling.
Having revealed that CXCR4, CXCR7 and CD24 were 
differentially expressed in more mesenchymal MDA‑MB‑231 
cells (40) compared with MDA‑MB‑468 cells in their more 
epithelial state (17), the expression of these targets were 
investigated in MDA‑MB‑468 cells following EGF‑ and 
hypoxia‑induced EMT. Induction of EMT with EGF in 
MDA‑MB‑468 cells decreased CXCR4 mRNA levels while 
the hypoxia‑induced EMT was associated with a significant 
increase in CXCR4 levels. This suggests that the induction of 
the EMT via EGF and hypoxia differentially affects CXCR4 
expression in MDA‑MB‑468 cells. Bertran et al (41) previ‑
ously demonstrated an increase in CXCR4 expression in 
rat hepatoma cells treated with transforming proliferation 
factor‑β to induce the EMT. Hence, transcriptional regulation 
of CXCR4 may differ depending on the EMT stimuli and may 
not be a fundamental characteristic of a more mesenchymal 
state. In the present study, CXCR7 levels were unaltered 
during hypoxia‑ and EGF‑induced EMT in MDA‑MB‑468 
cells. Hypoxia‑ and EGF‑induced EMT in MDA‑MB‑468 
cells produced a significant decrease in levels of CD24, 
consistent with its known association as a marker of the 
more epithelial state (31). CXCR4 and CXCR7 levels were 
enriched in the C‑Low molecular subtype of breast tumours 
compared with the basal molecular subtype. The C‑Low 
subtype is highly associated with metaplastic, EMT and stem 
cell‑like features (34,42). Hence, increased levels of CXCR4 
and CXCR7 in C‑Low sub‑types of breast cancer is consistent 
with the increased levels of these two receptors in the basal B 
MDA‑MB‑231 breast cancer cell line, which usually exhibits 
increased levels of mesenchymal markers (30) compared with 
the less mesenchymal basal A MDA‑MB‑468 cell line (30). 
Hence, significant differences in CXCL12‑induced Ca2+ 
signalling may also be a feature of different types of breast 
cancer and influence their invasive/metastatic properties. 
This should be the primary focus of future in vivo studies as 
methods of assessing Ca2+ signalling in xenografts continue 
to progress. In conclusion, these studies have defined distinct 
differences in CXCL12‑mediated Ca2+ signalling between 
MDA‑MB‑468 and MDA‑MB‑231 breast cancer cells. The 
present study also provides evidence for the occasional 
differential remodelling of potential Ca2+ signalling regula‑
tors as a consequence of EGF and hypoxia in MDA‑MB‑468 
breast cancer cells. It also provides evidence that CXCR4 and 
CXCR7 expression is enriched in breast tumours with mesen‑
chymal features.
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